CBD Life Sciences Inc. (CBDL) has entered the $2.8 billion global suppository market with the launch of its new line of CBD-infused vaginal and rectal suppositories, offering consumers an alternative delivery method for fast-acting, localized relief.
Cannabis suppository.
The Arizona-based company says its new products provide a unique approach to addressing issues such as menstrual cramps, endometriosis, pelvic floor dysfunction, gastrointestinal conditions, and chronic pelvic pain. Unlike oral CBD products that lose potency during digestion, suppositories bypass the digestive tract to deliver CBD directly into the bloodstream through the pelvic region or lower bowel.
The company says the suppositories are designed for both men and women and may help relieve symptoms of IBS, Crohn’s disease, hemorrhoids, prostatitis, and post-surgical inflammation. By targeting cannabinoid receptors in the digestive and reproductive systems, the suppositories aim to reduce inflammation, muscle tightness, and pain.
CBD Life Sciences cites growing demand for natural alternatives in women’s and gastrointestinal health as a key driver behind the launch. The global pharmaceutical suppositories market is projected to grow from $1.6 billion in 2022 to $2.8 billion by 2032, and CBDL sees its latest product as a strategic move into a high-potential, underserved space.
According to the company, several healthcare professionals in Scottsdale have already expressed interest in the product’s therapeutic potential for their patients.
CBD Life Sciences, which sells CBD and hemp-based products through direct-to-consumer, retail, and wholesale channels, has recently expanded distribution to platforms like Walmart Marketplace.
CBDL is publicly traded on OTC Markets under the ticker symbol CBDL.
